Lacosamide vs Phenytoin

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Epilepsy

Shared mechanism: Voltage-gated sodium channels · full Epilepsy pipeline

Lacosamide · Vimpat

Marketed by UCB

Approved in Epilepsysmall molecule
Reliable signal

NCT00136019 · Phase 3 · completed

Multicentre, double-blind, placebo-controlled trial (SP754): 405 patients randomised 1:2:1 to placebo, lacosamide 400 mg or 600 mg/day; the prespecified primary outcome was met. The registry record omits the arms; the design is from the publication.

The old registry record lists only the lacosamide intervention; the design and arms are from the publication.

Reported efficacy

Efficacy is evaluated based on reduction in seizure frequency, 50 percent reduction in seizures, number and percentage of seizure-free days, and achievement of seizure-free status.: Median % reduction in seizure frequency/28 days: lacosamide 400mg/day -37.3% (p=0.008), 600mg/day -37.8% (p=0.006), vs placebo -20.8%; >=50% responder rates 38.3% (400mg) and 41.2% (600mg) vs 18.3% placebo (p<0.001). (met)

Result source: NCT00136019

Phenytoin

Marketed by Viatris and partners

Approved in Epilepsysmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Epilepsy

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.

Key endpointLacosamidePhenytoin
Seizure frequency, % change—Not posted · NCT00136019—Not posted · NCT00210782
50% responder rate—Not posted · NCT00136019—Not posted · NCT00210782
Seizure freedom—Not posted · NCT00136019—Not posted · NCT00210782

Seizure frequency, % change

Lacosamide
—Not posted · NCT00136019
Phenytoin
—Not posted · NCT00210782

50% responder rate

Lacosamide
—Not posted · NCT00136019
Phenytoin
—Not posted · NCT00210782

Seizure freedom

Lacosamide
—Not posted · NCT00136019
Phenytoin
—Not posted · NCT00210782
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Lacosamide: 4 of 4 rows · Phenytoin: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricLacosamidePhenytoin
Dropout rate
34.3%a
NCT02408549 · Phase 3 · combination
show 45 more results
—Lacosamide (SS) Safety Follow-up P
NCT02408523 · Phase 3
—Lacosamide (SS) Taper Period
NCT02408523 · Phase 3
—Lacosamide (SS) Transition Period
NCT02408523 · Phase 3
—Lacosamide (SS) Treatment Period
NCT02408523 · Phase 3
7.1%
NCT01190098 · Phase 4 · registry result, not featured evidence
16.7%First Add-on
NCT00955357 · Phase 4 · registry result, not featured evidence · add on
18.3%Later Add-on
NCT00955357 · Phase 4 · registry result, not featured evidence · add on
36.8%Lacosamide: >=2 to <4 Years
NCT04627285 · Phase 3 · registry result, not featured evidence
13.8%Lacosamide: >=4 to <6 Years
NCT04627285 · Phase 3 · registry result, not featured evidence
26.9%
NCT01964560 · Phase 3 · registry result, not featured evidence
—
NCT02477839 · Phase 3 · registry result, not featured evidence
—
NCT02582866 · Phase 3 · registry result, not featured evidence
—
NCT01832038 · Phase 3 · registry result, not featured evidence
36.8%
NCT02124564 · Phase 3 · registry result, not featured evidence
11.7%
NCT01921205 · Phase 3 · registry result, not featured evidence
24.4%Lacosamide
NCT01465997 · Phase 3 · registry result, not featured evidence
—Lacosamide (SS)
NCT01465997 · Phase 3 · registry result, not featured evidence
40.1%
NCT01243177 · Phase 3 · registry result, not featured evidence
34.8%
NCT00530855 · Phase 3 · registry result, not featured evidence
0%
NCT02192814 · Phase 3 · registry result, not featured evidence
25%
NCT01345058 · Phase 3 · registry result, not featured evidence · combination
17.8%400 mg/day
NCT01710657 · Phase 3 · registry result, not featured evidence
6.6%200 mg/day
NCT01710657 · Phase 3 · registry result, not featured evidence
22.5%
NCT01484977 · Phase 3 · registry result, not featured evidence
39.2%400 mg/day
NCT00520741 · Phase 3 · registry result, not featured evidence
34.9%300 mg/day
NCT00520741 · Phase 3 · registry result, not featured evidence
57.4%
NCT00515619 · Phase 3 · registry result, not featured evidence
28.9%
NCT00655486 · Phase 3 · registry result, not featured evidence
55.2%
NCT00522275 · Phase 3 · registry result, not featured evidence
16%400 mg
NCT00655551 · Phase 3 · registry result, not featured evidence
6%300 mg
NCT00655551 · Phase 3 · registry result, not featured evidence
0%200 mg
NCT00655551 · Phase 3 · registry result, not featured evidence
—Lacosamide Age Cohort ≥ 1 Month -
NCT02710890 · Phase 2/3 · registry result, not featured evidence
—Lacosamide Age Cohort ≥ 8 - < 17 Y
NCT02710890 · Phase 2/3 · registry result, not featured evidence
—
NCT00938912 · Phase 2 · registry result, not featured evidence
10%Lacosamide 1 Month - <4 Years
NCT01969851 · Phase 2 · registry result, not featured evidence
33.3%Lacosamide 12 Years - <18 Years
NCT01969851 · Phase 2 · registry result, not featured evidence
12.5%Lacosamide 4 Years - <12 Years
NCT01969851 · Phase 2 · registry result, not featured evidence
—400mg
NCT01458522 · Phase 2 · registry result, not featured evidence
40%>=1 Month to <4 Years (Safety Set)
NCT00938431 · Phase 2 · registry result, not featured evidence
88.9%>=12 Years to <=17 Years (Safety S
NCT00938431 · Phase 2 · registry result, not featured evidence
39.1%>=4 Years to <12 Years (Safety Set
NCT00938431 · Phase 2 · registry result, not featured evidence
25.6%
NCT01118962 · Phase 2 · registry result, not featured evidence
18.4%
NCT01118949 · Phase 2 · registry result, not featured evidence
67.6%
NCT00552305 · Phase 2 · registry result, not featured evidence
38.2%a
NCT00510783 · Phase 4 · registry result, not featured evidence
Discontinued due to AEs
6.3%a
NCT02408549 · Phase 3 · combination
show 45 more results
—Lacosamide (SS) Safety Follow-up P
NCT02408523 · Phase 3
—Lacosamide (SS) Taper Period
NCT02408523 · Phase 3
—Lacosamide (SS) Transition Period
NCT02408523 · Phase 3
—Lacosamide (SS) Treatment Period
NCT02408523 · Phase 3
4.8%
NCT01190098 · Phase 4 · registry result, not featured evidence
9.4%First Add-on
NCT00955357 · Phase 4 · registry result, not featured evidence · add on
12.8%Later Add-on
NCT00955357 · Phase 4 · registry result, not featured evidence · add on
0%Lacosamide: >=2 to <4 Years
NCT04627285 · Phase 3 · registry result, not featured evidence
6.9%Lacosamide: >=4 to <6 Years
NCT04627285 · Phase 3 · registry result, not featured evidence
4.3%
NCT01964560 · Phase 3 · registry result, not featured evidence
—
NCT02477839 · Phase 3 · registry result, not featured evidence
—
NCT02582866 · Phase 3 · registry result, not featured evidence
—
NCT01832038 · Phase 3 · registry result, not featured evidence
10.5%
NCT02124564 · Phase 3 · registry result, not featured evidence
4.1%
NCT01921205 · Phase 3 · registry result, not featured evidence
4.3%Lacosamide
NCT01465997 · Phase 3 · registry result, not featured evidence
—Lacosamide (SS)
NCT01465997 · Phase 3 · registry result, not featured evidence
—
NCT01243177 · Phase 3 · registry result, not featured evidence
—
NCT00530855 · Phase 3 · registry result, not featured evidence
—
NCT02192814 · Phase 3 · registry result, not featured evidence
—
NCT01345058 · Phase 3 · registry result, not featured evidence · combination
15.6%400 mg/day
NCT01710657 · Phase 3 · registry result, not featured evidence
4.4%200 mg/day
NCT01710657 · Phase 3 · registry result, not featured evidence
6.7%
NCT01484977 · Phase 3 · registry result, not featured evidence
17.6%400 mg/day
NCT00520741 · Phase 3 · registry result, not featured evidence
15.1%300 mg/day
NCT00520741 · Phase 3 · registry result, not featured evidence
9%
NCT00515619 · Phase 3 · registry result, not featured evidence
10.3%
NCT00655486 · Phase 3 · registry result, not featured evidence
11.4%
NCT00522275 · Phase 3 · registry result, not featured evidence
16%400 mg
NCT00655551 · Phase 3 · registry result, not featured evidence
6%300 mg
NCT00655551 · Phase 3 · registry result, not featured evidence
0%200 mg
NCT00655551 · Phase 3 · registry result, not featured evidence
—Lacosamide Age Cohort ≥ 1 Month -
NCT02710890 · Phase 2/3 · registry result, not featured evidence
—Lacosamide Age Cohort ≥ 8 - < 17 Y
NCT02710890 · Phase 2/3 · registry result, not featured evidence
—
NCT00938912 · Phase 2 · registry result, not featured evidence
0%Lacosamide 1 Month - <4 Years
NCT01969851 · Phase 2 · registry result, not featured evidence
14.3%Lacosamide 12 Years - <18 Years
NCT01969851 · Phase 2 · registry result, not featured evidence
0%Lacosamide 4 Years - <12 Years
NCT01969851 · Phase 2 · registry result, not featured evidence
—400mg
NCT01458522 · Phase 2 · registry result, not featured evidence
33.3%>=1 Month to <4 Years (Safety Set)
NCT00938431 · Phase 2 · registry result, not featured evidence
66.7%>=12 Years to <=17 Years (Safety S
NCT00938431 · Phase 2 · registry result, not featured evidence
34.8%>=4 Years to <12 Years (Safety Set
NCT00938431 · Phase 2 · registry result, not featured evidence
5.1%
NCT01118962 · Phase 2 · registry result, not featured evidence
10.2%
NCT01118949 · Phase 2 · registry result, not featured evidence
13%
NCT00552305 · Phase 2 · registry result, not featured evidence
—a
NCT00510783 · Phase 4 · registry result, not featured evidence
Serious AEs
22.6%a
NCT02408549 · Phase 3 · combination
show 45 more results
9.1%Lacosamide (SS) Safety Follow-up P
NCT02408523 · Phase 3
0%Lacosamide (SS) Taper Period
NCT02408523 · Phase 3
3%Lacosamide (SS) Transition Period
NCT02408523 · Phase 3
6.6%Lacosamide (SS) Treatment Period
NCT02408523 · Phase 3
7.1%
NCT01190098 · Phase 4 · registry result, not featured evidence
8.3%First Add-on
NCT00955357 · Phase 4 · registry result, not featured evidence · add on
5.3%Later Add-on
NCT00955357 · Phase 4 · registry result, not featured evidence · add on
10.5%Lacosamide: >=2 to <4 Years
NCT04627285 · Phase 3 · registry result, not featured evidence
17.2%Lacosamide: >=4 to <6 Years
NCT04627285 · Phase 3 · registry result, not featured evidence
20.6%
NCT01964560 · Phase 3 · registry result, not featured evidence
4.7%
NCT02477839 · Phase 3 · registry result, not featured evidence
14.2%
NCT02582866 · Phase 3 · registry result, not featured evidence
17.5%
NCT01832038 · Phase 3 · registry result, not featured evidence
10.5%
NCT02124564 · Phase 3 · registry result, not featured evidence
6.4%
NCT01921205 · Phase 3 · registry result, not featured evidence
—Lacosamide
NCT01465997 · Phase 3 · registry result, not featured evidence
11.5%Lacosamide (SS)
NCT01465997 · Phase 3 · registry result, not featured evidence
8.1%
NCT01243177 · Phase 3 · registry result, not featured evidence
17.4%
NCT00530855 · Phase 3 · registry result, not featured evidence
0%
NCT02192814 · Phase 3 · registry result, not featured evidence
0%
NCT01345058 · Phase 3 · registry result, not featured evidence · combination
5%400 mg/day
NCT01710657 · Phase 3 · registry result, not featured evidence
1.1%200 mg/day
NCT01710657 · Phase 3 · registry result, not featured evidence
6.7%
NCT01484977 · Phase 3 · registry result, not featured evidence
6.6%400 mg/day
NCT00520741 · Phase 3 · registry result, not featured evidence
3.8%300 mg/day
NCT00520741 · Phase 3 · registry result, not featured evidence
23.1%
NCT00515619 · Phase 3 · registry result, not featured evidence
10.3%
NCT00655486 · Phase 3 · registry result, not featured evidence
23.1%
NCT00522275 · Phase 3 · registry result, not featured evidence
4%400 mg
NCT00655551 · Phase 3 · registry result, not featured evidence
0%300 mg
NCT00655551 · Phase 3 · registry result, not featured evidence
0%200 mg
NCT00655551 · Phase 3 · registry result, not featured evidence
0%Lacosamide Age Cohort ≥ 1 Month -
NCT02710890 · Phase 2/3 · registry result, not featured evidence
0%Lacosamide Age Cohort ≥ 8 - < 17 Y
NCT02710890 · Phase 2/3 · registry result, not featured evidence
22.5%
NCT00938912 · Phase 2 · registry result, not featured evidence
0%Lacosamide 1 Month - <4 Years
NCT01969851 · Phase 2 · registry result, not featured evidence
4.8%Lacosamide 12 Years - <18 Years
NCT01969851 · Phase 2 · registry result, not featured evidence
0%Lacosamide 4 Years - <12 Years
NCT01969851 · Phase 2 · registry result, not featured evidence
22.2%400mg
NCT01458522 · Phase 2 · registry result, not featured evidence
20%>=1 Month to <4 Years (Safety Set)
NCT00938431 · Phase 2 · registry result, not featured evidence
0%>=12 Years to <=17 Years (Safety S
NCT00938431 · Phase 2 · registry result, not featured evidence
13%>=4 Years to <12 Years (Safety Set
NCT00938431 · Phase 2 · registry result, not featured evidence
7.7%
NCT01118962 · Phase 2 · registry result, not featured evidence
2%
NCT01118949 · Phase 2 · registry result, not featured evidence
33.8%
NCT00552305 · Phase 2 · registry result, not featured evidence
0%a
NCT00510783 · Phase 4 · registry result, not featured evidence
Most frequent reported AEs
a
headache 23.4%
dizziness 22.2%
nasopharyngitis 21.8%
NCT02408549 · Phase 3 · combination
show 44 more results
dizziness 0% (placebo 0%)
drooling 0% (placebo 0%)
dyspepsia 0% (placebo 0%)
NCT02408523 · Phase 3
drooling 11.1% (placebo 0%)
grand mal convulsion 11.1% (placebo 0%)
laceration 11.1% (placebo 0%)
NCT02408523 · Phase 3
dizziness 3% (placebo 0%)
nasopharyngitis 1% (placebo 0%)
vertigo 1% (placebo 0%)
NCT02408523 · Phase 3
dizziness 21.5% (placebo 0%)
somnolence 14.9% (placebo 0%)
headache 13.2% (placebo 0%)
NCT02408523 · Phase 3
dizziness 42.9% (placebo 30%)
headache 40.5% (placebo 40%)
common cold/flu 21.4% (placebo 10%)
NCT01190098 · Phase 4 · registry result, not featured evidence
dizziness 31.3%
headache 13.5%
vertigo 9.4%
NCT00955357 · Phase 4 · registry result, not featured evidence · add on
dizziness 33.1%
somnolence 15%
headache 11.4%
NCT00955357 · Phase 4 · registry result, not featured evidence · add on
upper respiratory tract infection 26.3%
NCT04627285 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 13.8%
NCT04627285 · Phase 3 · registry result, not featured evidence
pyrexia 15.9%
upper respiratory tract infection 15.4%
nasopharyngitis 10.6%
NCT01964560 · Phase 3 · registry result, not featured evidence
somnolence 14.1% (placebo 3.9%)
irritability 5.5% (placebo 4.7%)
pyrexia 5.5% (placebo 11.8%)
NCT02477839 · Phase 3 · registry result, not featured evidence
headache 10.4%
nasopharyngitis 7.5%
NCT02582866 · Phase 3 · registry result, not featured evidence
nasopharyngitis 33%
dizziness 26.4%
upper respiratory tract infection 20.9%
NCT01832038 · Phase 3 · registry result, not featured evidence
dizziness 52.6%
somnolence 42.1%
nasopharyngitis 36.8%
NCT02124564 · Phase 3 · registry result, not featured evidence
somnolence 16.4% (placebo 6.4%)
nasopharyngitis 11.7% (placebo 5.8%)
dizziness 10.5% (placebo 7.6%)
NCT01921205 · Phase 3 · registry result, not featured evidence
nasopharyngitis 7.2%
headache 6.1%
dizziness 4.3%
NCT01465997 · Phase 3 · registry result, not featured evidence
headache 13.5%
dizziness 11.9%
fatigue 7.7%
NCT01243177 · Phase 3 · registry result, not featured evidence
dizziness 27.6%
headache 17.1%
nausea 14.3%
NCT00530855 · Phase 3 · registry result, not featured evidence
abdominal pain upper 11.1%
injection site erythema 11.1%
injection site pain 11.1%
NCT02192814 · Phase 3 · registry result, not featured evidence
erectile dysfunction 11.1%
fatigue 11.1%
memory/cognitive difficulties/confusion 11.1%
NCT01345058 · Phase 3 · registry result, not featured evidence · combination
400 mg/day
dizziness 35% (placebo 13%)
nasopharyngitis 16.1% (placebo 13%)
headache 10.6% (placebo 6%)
NCT01710657 · Phase 3 · registry result, not featured evidence
200 mg/day
dizziness 18% (placebo 13%)
nasopharyngitis 15.3% (placebo 13%)
somnolence 9.8% (placebo 4.9%)
NCT01710657 · Phase 3 · registry result, not featured evidence
dizziness 23.3%
headache 15%
fatigue 8.3%
NCT01484977 · Phase 3 · registry result, not featured evidence
400 mg/day
dizziness 27%
nausea 14.4%
headache 14.1%
NCT00520741 · Phase 3 · registry result, not featured evidence
300 mg/day
headache 19.8%
dizziness 17.9%
convulsion 16%
NCT00520741 · Phase 3 · registry result, not featured evidence
dizziness 24.2%
headache 14.4%
nasopharyngitis 13.8%
NCT00515619 · Phase 3 · registry result, not featured evidence
dizziness 44.3%
diplopia 17.5%
vomiting 16.5%
NCT00655486 · Phase 3 · registry result, not featured evidence
dizziness 50%
headache 21.8%
contusion 18.5%
NCT00522275 · Phase 3 · registry result, not featured evidence
400 mg
dizziness 60%
somnolence 36%
nausea 24%
NCT00655551 · Phase 3 · registry result, not featured evidence
300 mg
dizziness 46%
somnolence 34%
fatigue 18%
NCT00655551 · Phase 3 · registry result, not featured evidence
200 mg
dizziness 20%
gait disturbance 8%
headache 8%
NCT00655551 · Phase 3 · registry result, not featured evidence
functional gastrointestinal disorder 2.1%
pyrexia 2.1%
respiratory tract infection 2.1%
NCT02710890 · Phase 2/3 · registry result, not featured evidence
blood triglycerides increased 3.6%
blood cholesterol increased 1.8%
functional gastrointestinal disorder 0%
NCT02710890 · Phase 2/3 · registry result, not featured evidence
nasopharyngitis 24.9%
upper respiratory tract infection 23.6%
pyrexia 21.9%
NCT00938912 · Phase 2 · registry result, not featured evidence
nasopharyngitis 50%
pyrexia 40%
somnolence 40%
NCT01969851 · Phase 2 · registry result, not featured evidence
headache 19%
nasopharyngitis 14.3%
pharyngotonsillitis 14.3%
NCT01969851 · Phase 2 · registry result, not featured evidence
pyrexia 25%
cough 16.7%
upper respiratory tract infection 16.7%
NCT01969851 · Phase 2 · registry result, not featured evidence
400mg
respiratory failure 6.7%
acute respiratory failure 4.4%
bradycardia 4.4%
NCT01458522 · Phase 2 · registry result, not featured evidence
irritability 20%
pharyngotonsillitis 20%
diarrhoea 13.3%
NCT00938431 · Phase 2 · registry result, not featured evidence
balance disorder 22.2%
dizziness 22.2%
rash 22.2%
NCT00938431 · Phase 2 · registry result, not featured evidence
vomiting 30.4%
diarrhoea 17.4%
dizziness 13%
NCT00938431 · Phase 2 · registry result, not featured evidence
dizziness 25.6%
upper respiratory tract infection 25.6%
headache 17.9%
NCT01118962 · Phase 2 · registry result, not featured evidence
dizziness 38.8%
nausea 26.5%
headache 16.3%
NCT01118949 · Phase 2 · registry result, not featured evidence
dizziness 39.7%
headache 20.8%
nausea 17.3%
NCT00552305 · Phase 2 · registry result, not featured evidence
a
dizziness 9.2%
fatigue 9.2%
burning at the iv site 6.6%
NCT00510783 · Phase 4 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Lacosamide

Convulsive Seizure Frequency -88.58% (n=238)
percent change · % of baseline
No placebo or comparator arm
NCT02408549 · Phase 3 · combination
Time to Second PGTC Seizure 49 vs 76 placebo count @ 24wk
event count · count
NCT02408523 · Phase 3
PGTC Seizure Free 31% (n=118) vs 17.3% (n=121) placebo @ 24wk
responder rate · % of participants
NCT02408523 · Phase 3
Time to First PGTC Seizure 79 vs 97 placebo count @ 24wk
event count · count
NCT02408523 · Phase 3
ESS -1.2 vs -1.1 placebo score
absolute change · score
NCT01190098 · Phase 4 · registry result, not featured evidence
FSS 0.3 vs -5.4 placebo score
absolute change · score
NCT01190098 · Phase 4 · registry result, not featured evidence
PSQI -1.6 vs -1.3 placebo score
absolute change · score
NCT01190098 · Phase 4 · registry result, not featured evidence
PHQ-9 -1.1 vs -1.2 placebo score
absolute change · score
NCT01190098 · Phase 4 · registry result, not featured evidence
QOLIE-31-P 4 vs 4.2 placebo score
absolute change · score
NCT01190098 · Phase 4 · registry result, not featured evidence
Seizure-free 37.5% (n=72) @ 18wk
responder rate · % of participants
Maintenance
No placebo or comparator arm
NCT00955357 · Phase 4 · registry result, not featured evidence · add on
show 1 more result
14.9% (n=261) @ 18wk
NCT00955357 · Phase 4 · registry result, not featured evidence · add on
Seizure-free 66.96 % of time
absolute value · % of time
No placebo or comparator arm
NCT01964560 · Phase 3 · registry result, not featured evidence
Partial Onset Seizure Frequency -48.78% (n=179) vs -10.1% (n=183) placebo @ 24wk400 mg/day
percent change · % of baseline
Maintenance
NCT01710657 · Phase 3 · registry result, not featured evidence
show 3 more results
-36.75% (n=182) vs -10.1% (n=183) placebo @ 24wk200 mg/day
NCT01710657 · Phase 3 · registry result, not featured evidence
1.4% (n=116) vs 1.44% (n=120) placebo @ 4wk
NCT02477839 · Phase 3 · registry result, not featured evidence
-32.3564% (n=121) vs -26.7927% (n=122) placebo @ 4wk
NCT02477839 · Phase 3 · registry result, not featured evidence

+ 25 further endpoints in the CSV export.

Phenytoin

Seizure Recurrence 24 h 3.9% (n=76) vs 2.4% (n=82) Phenytoin/Fosphenytoin @ 0.142857wk
event count · % of participants
NCT00510783 · Phase 4 · registry result, not featured evidence · converted to % from 3 participants as posted

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lacosamide's landscape · Phenytoin's landscape